Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10426582 | 0.79 | TSHR (0.48) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL4434268 | 0.79 | TSHR (0.48) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL16469354 | 0.77 | TSHR (0.46) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL10128271 | 0.77 | TSHR (0.46) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL25285395 | 0.75 | TSHR (0.43) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL5595512 | 0.75 | TSHR (0.43) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL263167 | 0.75 | TSHR (0.43) | TSHRTP53TDP1PPARD | |
| SCHEMBL4757795 | 0.75 | TSHR (0.43) | TSHRTP53TDP1PPARD | |
| SCHEMBL38659955 | 0.75 | TP53 (0.46) | TSHRTP53TDP1PPARDACHE | |
| Bromide SCHEMBL2692145 | 0.73 | TSHR (0.48) | TSHRTP53TDP1PPARDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131908-B2 | 5′ phosphate mimics | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20150080457-A1 | 5' PHOSPHATE MIMICS | BANK OF AMERICA, N.A. | 2015-03-19 | — | — | US | disclosed |
| US-8927513-B2 | 5′ phosphate mimics | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011005860-A2 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | NSUN2, RNGTT, RNMT | TSHR 3336/4885TP53 919/4885TDP1 514/4885 |
| US-20150080457-A1 | 5' PHOSPHATE MIMICS | NSUN2, RNGTT, RNMT | TSHR 3344/4885TP53 919/4885TDP1 518/4885 |
| US-10131908-B2 | 5′ phosphate mimics | NSUN2, RNGTT, RNMT | TSHR 3339/4885TP53 931/4885TDP1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.